InsidersTradesSigma
Track the Metagenomi Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €45.6m. The latest transaction was reported on 3 April 2026 (Attribution). Among the most active insiders: Wapnick Pamela. All data is free.
Analysts rate Metagenomi Therapeutics, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$7.67.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
6 of 6 declarations
Metagenomi Therapeutics, Inc. es una empresa de biotecnología centrada en el desarrollo de terapias génicas innovadoras. Aprovecha tecnologías avanzadas para abordar enfermedades genéticas y otras afecciones médicas.